Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Flávio Sabino"'
Autor:
Flávio Sabino, Luciana Ribeiro, Daniel Fernandes, Marco Guimarães-Filho, Luis Felipe Ribeiro Pinto, Michel Carneiro
Publikováno v:
Diseases of the Esophagus. 34
Neoadjuvant treatment followed by esophagectomy is the standard therapy for patients with resectable esophageal cancer. Data have demonstrated that patients with pathologic complete response (pCR) have better survival. Several studies have been explo
Publikováno v:
Diseases of the Esophagus. 34
Neoadjuvant chemoradiation (CR) became the standard of care for the treatment of resectable esophageal cancer, but the survival rates are still worse than the observed in other gastrointestinal malignancies. The optimal neoadjuvant approach is still
Publikováno v:
Diseases of the Esophagus. 34
The standard esophageal replacement after esophagectomy for cancer treatment is a gastric conduit, as it is a simpler technique than the other options available, requiring only one anastomosis. However, when the stomach is not available, a left- or r
Autor:
Alexandre Palladino, André Maciel da Silva, Antônio Carlos Acetta, Flávio Sabino, Flora Lino, Luciana Ribeiro, Sérgio Bertolace, Daniel Cesar
O câncer gástrico (CG) é a terceira principal causa de morte por câncer em ambos os sexos e a quinta neoplasia maligna mais comum em todo o mundo. Possui distribuição global heterogênea, sendo mais incidente no leste asiático, no leste europe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2ac941b9cd3e258082713f8e31550bd4
https://doi.org/10.56271/978.65.87679.50.1-8
https://doi.org/10.56271/978.65.87679.50.1-8
Autor:
Maria Ribeiro Santos Morard, Tereza Guedes, Flávio Sabino, Carlos Bernardo Cola, Pedro Eder Portari Filho, Carlos Eduardo Pinto
Publikováno v:
Revista do Colégio Brasileiro de Cirurgiões, Vol 44, Iss 5, Pp 428-434
Revista do Colégio Brasileiro de Cirurgiões, Volume: 44, Issue: 5, Pages: 428-434, Published: OCT 2017
Revista do Colégio Brasileiro de Cirurgiões v.44 n.5 2017
Revista do Colégio Brasileiro de Cirurgiões
Colégio Brasileiro de Cirurgiões (CBC)
instacron:CBC
Revista do Colégio Brasileiro de Cirurgiões, Volume: 44, Issue: 5, Pages: 428-434, Published: OCT 2017
Revista do Colégio Brasileiro de Cirurgiões v.44 n.5 2017
Revista do Colégio Brasileiro de Cirurgiões
Colégio Brasileiro de Cirurgiões (CBC)
instacron:CBC
Objective: to analyze the National Cancer Institute Abdominopelvic Division (INCA / MS/HC I) initial experience with thoraco-laparoscopic esophagectomy with thoracic stage in prone position. Methods: we studied 19 consecutive thoraco-laparoscopic eso
Autor:
Flávio Sabino, Daniel Fernandes, Luis Felipe Ribeiro Pinto, Marco Antonio Guimaraes, Luciana Ribeiro, Carlos Eduardo Pinto, Flávia Nascimento de Carvalho
Publikováno v:
European Journal of Surgical Oncology. 46:e149
Autor:
Simone Guaraldi, Eduardo Camara, Alexandre Pelosi, Marco Antonio Guimaraes Filho, Gustavo Mello, Andre Ferreira, Flávio Sabino
Publikováno v:
Diseases of the Esophagus. 31:101-102
Background Anastomotic leaks after esophagectomy can lead to severe complications and account for 40% of postoperative deaths. During the last decades, several types of endoscopic treatments have became available, such as the use of esophageal stent
Autor:
Rafael Albagli, Flávio Sabino, Luis Felipe Pinto, Carlos Eduardo Pinto, Daniel Fernandes, Marco Antonio Guimaraes, Luciana Ribeiro
Publikováno v:
Diseases of the Esophagus. 31:159-160
Background Surgical resection is considering the gold standard in esophageal cancer treatment, with 15–40% cure global rates. Radical exclusive chemoradiotherapy (CRT) is used in patients with local advanced esophageal cancer or without clinical co
Autor:
Carlos Eduardo Pinto, Flávio Sabino, Luciana Ribeiro, Marco Antonio Guimaraes Filho, Luis Felipe Pinto, Daniel Fernandes
Publikováno v:
Diseases of the Esophagus. 31:102-102
Background Esophageal cancer is the 8th most common cancer in the world. It is an lethal disease, responsible for almost 400.000 deaths by year. Surgical resection is considered the gold standard in esophageal cancer treatment, with a global 15–40%